Benzinga | Nov 11, 2021 04:34AM EST

Keybanc Maintains Overweight on Exagen, Lowers Price Target to $30

Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price target from $33 to $30.